Women in Biotech - London
Wednesday 4 March 2020
This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion.
The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech event this March. Join us on Wednesday 4 March to hear about Women Ahead of Their Time (WATT).
This event is now fully booked and online registration has closed. The next Women in Biotech event will run on 4 June in Oxford.
18.00 Registration and networking
Jane Wall, Director of Business Development and Membership Services, BIA
Eleanor Root, Partner - Intellectual Property, Bird & Bird
Ros Deegan, CEO, OMass Therapeutics
18.50 Introduction to Women Ahead of Their Time (WATT) - Agnieszka Wabik, Co-founder, WATT
18.55 Panel discussion and Q&A
Ros Deegan, CEO, OMass Therapeutics
Jessica Santivanez, Senior Scientist, GSK
Silvia De Alessandris, Manager in Healthcare and Life Sciences strategy, KPMG UK
Zuzanna Brzosko, CEO and Co-Founder, Sixfold Bioscience
19.30 Closing remarks
19.35 Networking and drinks
Bird & Bird LLP
12 New Fetter Lane
Transport: The venue is in central London and easily reached by public transport. It is within 10 minutes walk of Chancery Lane, Temple, and Blackfriars stations.
Women Ahead of Their Time (WATT)
WATT is a new not-for-profit organisation aimed at inspiring younger generations by showcasing stories of female professionals in their early stage careers in STEM. Through WATT, these extraordinary women share with the world their unique journey to success, including the struggles and failures along the way.
There is no magic recipe for success, but passion and determination are a commonplace. Join the WATT team at the BIA Women in Biotech event for the official launch of the website and panel discussion with young professionals in bioindustry.
I'm a partner in the Intellectual Property Group based in London specialising in contentious patent matters with a particular focus and keen interest in the life sciences and healthcare sector.
Over the years, my particular expertise and focus has been developed through my involvement in and management of numerous commercially important, multi-jurisdictional and technically complex cases mainly in the field of pharmaceutical/biological patents for both innovator and generic clients up to the Supreme Court.
I have also built up complementary experience in advising and supporting our clients in a range of sectors in relation to their multi-jurisdictional patent portfolio management and strategy (including associated proceedings/enforcement and commercialisation), freedom to operate/validity and infringement analyses, specific regulatory considerations and IP due diligence and disclosure in corporate transactions.
In recent years, I have supported two multinational pharma clients on secondment in-house managing a heavy and diverse multi-jurisdictional workload spanning commercial, regulatory and IP litigation matters. This valuable experience has enabled me to gain a deeper understanding of the different business functions, the pharmaceutical regulatory regime and the varying public policy and health system issues which have become increasingly relevant to European patent/SPC litigation and strategy.
Ros Deegan has been CEO of OMass Therapeutics for less than a year but has already led an expansion of the company’s Series A financing to a total of £41.5m. Prior to OMass, Ros served as President, CBO and a Director of the US subsidiary of Bicycle Therapeutics. Ros established the company’s Boston-based subsidiary and over a three-year period led three major transactions and grew the US operations to more than 20 employees.
Prior to Bicycle, Ros served as SVP Business Development and Operations at Trevena where she had previously held the role of Head of Finance and Operations. During Ros’ tenure at Bicycle and Trevena, the companies moved four programs into the clinic, and raised over $300m in public and private financings. In her earlier career, Ros was Director of Business Development at GSK in the US, and prior to that she served as Director of Operations for GSK’s Center of Excellence for External Drug Discovery (CEEDD) and as Marketing Manager for GSK’s UK launch of Bonviva for post-menopausal osteoporosis. Ros is a graduate of Cambridge University and received her MBA with distinction from INSEAD.
Agnieszka is a co-founder of WATT. She completed a PhD at the University of Cambridge focusing on early cancer development. She was supporting the development and implementation of the scientific strategy while working at the Experimental Cancer Medicines Centres Network at Cancer Research UK. Currently, she works as a freelance scientific consultant for Inspiralia, coordinating multidisciplinary teams to help formulate innovation strategy and fundraising for biotechnology start-ups and scientific partnerships.
Jessica is a Senior Scientist at GSK with strong expertise in assay development for early drug discovery. She has rotated across functions to work with small molecules, biopharms and data science. Before transitioning to the pharmaceutical industry, she completed a PhD at the University of Cambridge focusing on neurodegeneration research.
Silvia De Alessandris
Silvia is a biotechnologist by background. After her PhD at the University of Cambridge, a collaboration with biotech company MedImmune Ltd, attracted by the interface between science and business, she decided to make a career in strategy consulting. For the last 4 years Silvia has supported Top 20 pharmaceutical companies with their commercialisation and growth strategies, specialising in pricing and market access of novel therapies.
Dr Zuzanna Brzosko is the co-founder and CEO of Sixfold Bioscience, a Y Combinator and venture-backed biotechnology company focused on developing drug delivery systems for Cell and Gene therapeutics.
Zuzanna completed her PhD and postdoctoral training at Cambridge University and her undergraduate degree at Oxford University. Following her academic work, she worked in investment banking at Goldman Sachs before founding Sixfold. Zuzanna has been recognized by the Forbes 30U30 in Science/Healthcare, the Maserati’s Top 100 British Entrepreneurs and Aviva’s Women of the Future in Science, amongst others.
The BIA’s Women in Biotech event series has been running for over 12 years and aims to connect, inspire, and support women across the sector.